Analysed ADAPTIVE BIOTECHNOLOGIES (ADPT:NASDAQ) News Sources
Adaptive Biotechnologies (ADPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
05-05-2026
yahoo.com
Assessing Adaptive Biotechnologies (ADPT) Valuation After Strong MRD Growth And Raised Full Year Guidance
11-05-2026
yahoo.com
Harvest Investment Services Dumps 356,000 Adaptive Biotechnologies (ADPT) Shares Worth $5.7 Million
26-05-2026
fool.com
At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research
29-05-2026
yahoo.com
Adaptive Biotech (ADPT) Reports 35% Revenue Growth Driven by Strong clonoSEQ Performance in Q1 2026
03-06-2026
yahoo.com
Adaptive Biotechnologies Highlights clonoSEQ Growth, 2026 Cash Flow Goal at Conference
03-06-2026
marketbeat.com
How The Adaptive Biotechnologies (ADPT) Narrative Is Shifting Around A US$20 Fair Value Anchor
04-06-2026
yahoo.com
OpenFold Consortium Adds Eleven New Members as Momentum Builds for Open AI Infrastructure in Biology and Drug Discovery
09-06-2026
yahoo.com
What is the current price of ADAPTIVE BIOTECHNOLOGIES (ADPT:NASDAQ)?
The current price of ADAPTIVE BIOTECHNOLOGIES (ADPT:NASDAQ) is $17.6.
ADAPTIVE BIOTECHNOLOGIES (ADPT:NASDAQ) absolute price change since previous trading day?
The absolute price change of ADAPTIVE BIOTECHNOLOGIES (ADPT:NASDAQ) since the previous trading day is $-1.13.
ADAPTIVE BIOTECHNOLOGIES (ADPT:NASDAQ) percentage price change since previous trading day?
The percentage price change of ADAPTIVE BIOTECHNOLOGIES (ADPT:NASDAQ) since the previous trading day is -6.0331%.
What is the most recent average sentiment score for ADAPTIVE BIOTECHNOLOGIES (ADPT:NASDAQ)?
The most recent average sentiment score for ADAPTIVE BIOTECHNOLOGIES (ADPT:NASDAQ) is 83 out of 100.
What is the most recent average sentiment for ADAPTIVE BIOTECHNOLOGIES (ADPT:NASDAQ)?
The most recent sentiment for ADAPTIVE BIOTECHNOLOGIES (ADPT:NASDAQ) is .
SEC-8K** Filing Available For ADAPTIVE BIOTECHNOLOGIES (ADPT:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.